menu

When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    This discussion is part of a series titled "When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options".

  • Educational information

    This discussion is part of a series titled "When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options".

  • Faculty

    Prof. John McMurray, MD (Glasgow, UK), Prof. Carolyn Lam, MD, PhD (Singapore), and Prof. Scott Solomon, MD (Boston, MA, USA)

  • Disclosures

    This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

  • Funding

    Funding for this educational program was provided by an unrestricted educational grant from AstraZeneca.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    This discussion is part of a series titled "When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options".

  • Educational information

    This discussion is part of a series titled "When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options".

  • Faculty

    Prof. John McMurray, MD (Glasgow, UK), Prof. Carolyn Lam, MD, PhD (Singapore), and Prof. Scott Solomon, MD (Boston, MA, USA)

  • Disclosures

    This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

  • Funding

    Funding for this educational program was provided by an unrestricted educational grant from AstraZeneca.

Facebook Comments

Schedule14 Jun 2024